Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Enzalutamide (Xtandi) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 12 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Enzalutamide (Xtandi).** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: 1-866-331-2104]. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: http://pithelp.appl.kp.org/MAS/formulary.html**

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Provider Information

Prescriber specialty: □ Hematologist □ Oncologist □ Other: _____

If consulted with a specialist, specialist name and specialty: _____

Provider Name: _____ Provider NPI: _____

Provider Address: _____

Provider Phone #: _____Provider Fax #: _____

Please check the boxes that apply:
□ Initial Request □ Continuation of Therapy Request

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone #_____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____
Sig: _____

Drug 2: Name/Strength/Formulation: _____
Sig: _____

5 – Diagnosis

Please document Indication:

□ Metastatic Castration-Sensitive Prostate Cancer

□ Metastatic Castration-Resistant Prostate Cancer

□ Non-Metastatic Castration-Resistant Prostate Cancer

□ Other: _____

6–Clinical Criteria

Initial Therapy:

Metastatic Castration-Sensitive Prostate Cancer

1. Does the member have both of the following?
    a. □ No □ Yes Metastatic castration-sensitive prostate cancer
    b. □ No □ Yes History of treatment failure, intolerance, or contraindication to abiraterone

Metastatic Castration-Resistant Prostate Cancer

1. Does the member have both of the following?
    a. □ No □ Yes Metastatic castration-resistant prostate cancer
    b. □ No □ Yes History of treatment failure, intolerance, or contraindication to abiraterone

Non-Metastatic Castration-Resistant Prostate Cancer

1. Does the member have both of the following?
    a. □ No □ Yes Non-metastatic castration-resistant prostate cancer
    b. □ No □ Yes High risk for development of metastasis defined as a PSADT ≤10 months during continuous androgen-deprivation therapy (bilateral orchiectomy or treatment with gonadotropin-releasing hormone analogue agonists)

Continuation of Therapy:

1. Member does NOT show evidence of progressive disease while on therapy. □ No □ Yes

7 – Provider Sign-Off

Additional Information – Please provide any additional information that should be taken into consideration.

_____

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Provider Signature:	**Date:**

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility